8-K filed February 18, 2026, 6:59 PM ET ticker CIMG CIK 0001527613

earnings confidence high sentiment positive materiality 0.75

CIMG reports FY2025 revenue $10.3M (+433% YoY); net loss down 45.5%; Nasdaq bid price regained

CIMG Inc.

2026-Q1 EPS reported -$1.43 revenue$15,768,796

Revenue of $10.3M in FY2025, up ~433% YoY, driven by new computing power and digital health contracts.
Net loss decreased ~45.5% YoY, reflecting improved operational efficiency and cost optimization.
Held ~500 Bitcoins valued at ~$57.05M as of Sept 30, 2025; total assets up 1,227% YoY.
Regained compliance with Nasdaq minimum bid price rule; subject to one-year discretionary panel monitor.
Book value per share ~$2.99 based on shares outstanding.

item 3.01 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-007338
form_type: 8-K
ticker: CIMG
cik: 0001527613
company_name: CIMG Inc.
filed_at: 2026-02-18T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.332452+00:00
generated_at: 2026-05-16T02:02:16.130279+00:00
sec_items: ["3.01", "7.01", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-007338
json_url: https://secwatch.observer/filing/0001493152-26-007338.json
markdown_url: https://secwatch.observer/filing/0001493152-26-007338.md
text_url: https://secwatch.observer/filing/0001493152-26-007338.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1527613/000149315226007338/0001493152-26-007338-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1527613/000149315226007338/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

c8eab4bb884ef476453db30a45c7391e65dd6e55

CIMG Inc. received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).

February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the U.S. Securities and Exchange Commission. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the Company will be subject to a discretionary panel monitor for a period of one year from February 10, 2026. If, within that one-year monitoring period, the Nasdaq staff (the “Staff”) finds the Company again out of compliance with any Nasdaq listing rule, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with r

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

f462c7c54e6efb3edc0b57d8ea4dde109795ed7a

CIMG Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

February 10, 2026, CIMG Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Hearings office confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), the Minimum Bid Price Requirement. The Company remains subject to a Hearing Panel exception to demonstrate compliance with Nasdaq Listing Rule 5250(c)(1), the Periodic Filing Requirement. On February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the U.S. Securities and Exchange Commission. In addition, pursuant to Nasdaq Listing

SEC 8-K Item 3.01 confidence 0.9 SEC evidence

Comparable filings

RANI

Rani Therapeutics Q1 net loss narrows to $8M; Nasdaq bid price non-compliance; CFO to depart

Rani Therapeutics Holdings, Inc. May 15, 2026, 4:08 PM ET earnings Items 2.02, 3.01, 5.02, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 9.01 same event type: earnings similar materiality

This filing

February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the U.S. Securities and Exchange Commission. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the Company will be subject to a discretionary panel monitor for a period of one year from February 10, 2026. If, within that one-year monitoring period, the Nasdaq staff (the “Staff”) finds the Company again out of compliance with any Nasdaq listing rule, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with r

Comparable filing

May 11, 2026, the Company received a letter from the Nasdaq Stock Exchange LLC (“Nasdaq”), notifying the Company that, based on the closing bid price of the Company’s Class A common stock, par value $0.0001 per share (th

Filing page SEC filing

GENC

Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing

GENCOR INDUSTRIES INC June 1, 2026, 4:09 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 similar materiality

This filing

February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the U.S. Securities and Exchange Commission. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the Company will be subject to a discretionary panel monitor for a period of one year from February 10, 2026. If, within that one-year monitoring period, the Nasdaq staff (the “Staff”) finds the Company again out of compliance with any Nasdaq listing rule, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with r

Comparable filing

May 19, 2026, Gencor Industries, Inc. (the “Company”) received a notice (the “Delinquency Notification”) from NYSE Regulation (the “NYSE”) indicating the Company was not in compliance with the NYSE American LLC (“NYSE American”) continued listing standards as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the Securities and Exchange Commission (“SEC”) prior to May 18, 2026, the end of the extension period provided by Form 12b-25, and as a result was subject to the procedures set forth in Section 1007 of the NY

Filing page SEC filing

ATNM

Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26

Actinium Pharmaceuticals, Inc. May 29, 2026, 5:10 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 similar materiality

This filing

February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the U.S. Securities and Exchange Commission. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the Company will be subject to a discretionary panel monitor for a period of one year from February 10, 2026. If, within that one-year monitoring period, the Nasdaq staff (the “Staff”) finds the Company again out of compliance with any Nasdaq listing rule, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with r

Comparable filing

May 27, 2026, Actinium Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31, 2026, the Company reported stockholders’ equity of approximately

Filing page SEC filing

CDT

CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan

CDT Equity Inc. May 28, 2026, 4:30 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 similar materiality

This filing

February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the U.S. Securities and Exchange Commission. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the Company will be subject to a discretionary panel monitor for a period of one year from February 10, 2026. If, within that one-year monitoring period, the Nasdaq staff (the “Staff”) finds the Company again out of compliance with any Nasdaq listing rule, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with r

Comparable filing

May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued listing on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s

Filing page SEC filing

GWAV

Greenwave receives second Nasdaq delinquency notice for late Q1 2026 10-Q filing

Greenwave Technology Solutions, Inc. May 27, 2026, 5:25 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 similar materiality

This filing

February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the U.S. Securities and Exchange Commission. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the Company will be subject to a discretionary panel monitor for a period of one year from February 10, 2026. If, within that one-year monitoring period, the Nasdaq staff (the “Staff”) finds the Company again out of compliance with any Nasdaq listing rule, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with r

Comparable filing

May 21, 2026, the Company received an additional delinquency notification letter (the “Notice”) from Nasdaq due to the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March

Filing page SEC filing

CHAR

Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing

Charlton Aria Acquisition Corp May 27, 2026, 4:41 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 similar materiality

This filing

February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the U.S. Securities and Exchange Commission. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the Company will be subject to a discretionary panel monitor for a period of one year from February 10, 2026. If, within that one-year monitoring period, the Nasdaq staff (the “Staff”) finds the Company again out of compliance with any Nasdaq listing rule, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with r

Comparable filing

May 22, 2026, Charlton Aria Acquisition Corporation (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that

Filing page SEC filing

BRLS

Borealis Foods receives Nasdaq deficiency notice for delayed Q1 2026 10-Q; supplements prior 2025 10-K notice

Borealis Foods Inc. May 27, 2026, 4:15 PM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 similar materiality

This filing

February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the U.S. Securities and Exchange Commission. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the Company will be subject to a discretionary panel monitor for a period of one year from February 10, 2026. If, within that one-year monitoring period, the Nasdaq staff (the “Staff”) finds the Company again out of compliance with any Nasdaq listing rule, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with r

Comparable filing

May 21, 2026, a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, because the Company has not yet filed the Q12026 Form 10-Q, the Company no longer complies with Nasdaq Lis

Filing page SEC filing

FSHP

Flag Ship Acquisition receives second Nasdaq deficiency notice for late Q1 10-Q filing

Flag Ship Acquisition Corp May 27, 2026, 9:10 AM ET regulatory Items 3.01, 7.01, 9.01

same fact type: exchange_compliance_notice same SEC item: 3.01, 7.01, 9.01 similar materiality

This filing

February 13, 2026, the Company filed its Annual Report on Form 10-K for the fiscal year ended September 30, 2025 with the U.S. Securities and Exchange Commission. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the Company will be subject to a discretionary panel monitor for a period of one year from February 10, 2026. If, within that one-year monitoring period, the Nasdaq staff (the “Staff”) finds the Company again out of compliance with any Nasdaq listing rule, notwithstanding Rule 5810(c)(2), the Company will not be permitted to provide the Staff with a plan of compliance with r

Comparable filing

May 21, 2026, Flag Ship Acquisition Corporation (the “Company”) received an additional deficiency letter (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) as a res

Filing page SEC filing

Source: SEC EDGAR

accession 0001493152-26-007338

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.